In recent years mesenchymal stromal cells (MSCs) emerged as a promising therapeutic option for various diseases due to their immunomodulatory properties. We previously observed that intraperitoneally injected MSCs in experimental colitis form spherical shaped aggregates. Therefore, we aggregated MSCs in vitro into spheroids and injected them intraluminally in mice with established colitis to investigate whether these MSC spheroids could alleviate the colitis.
INTRODUCTION
Due to their immunomodulatory properties and their ability to actively participate in tissue repair mesenchymal stromal cells (MSCs) emerged as a potential therapeutic alternative in the treatment of several diseases. 1 Promising reports on the use of MSCs as a treatment for both experimental colitis as well as human inflammatory bowel disease (IBD) have been published in the last few years. [2] [3] [4] [5] [6] Currently, their exact mode of action is under investigation.
Previously it became clear that MSC-therapy is not beneficial under all conditions of an ongoing immune response and that the timing of administration is important to induce the full immunosuppressive and tissue regenerative properties of MSCs. 7 In recent years, potentiating the therapeutic efficacy of MSCs, by priming with proinflammatory cytokines such as interferon-gamma (IFN-ɣ) and/or tumor necrosis factor-alpha (TNF-α) to create an immunostimulatory milieu in vitro before use in vivo was also evaluated. 8, 9 Although encouraging results have been obtained in different preclinical studies using these primed MSCs 10, 11 , caution should be taken as MSCs can participate in antigen presentation by upregulation of major histocompatibility class (MHC) class II molecules when not primed sufficiently. This could finally result in a potential risk of rejection and exaggeration of an ongoing immune response, ultimately worsening the disease. 7, [12] [13] [14] [15] Therefore, new methods to increase the immunomodulatory effects of MSCs are relevant to be assessed. Recently, intraperitoneally injected MSCs were observed to cluster together to form aggregates which produced the anti-inflammatory protein tumor necrosis factor-inducible gene (TSG)-6 leading to attenuated dextran sulphate sodium (DSS)-induced colitis. 16 Remarkably, intravenously injected MSCs in experimental myocardial infarction entrapped within the lungs also formed clusters that produced TSG-6 thereby improving tissue damage. 17 In our previously performed experiments, we also observed that intraperitoneally injected MSCs form spherical shaped aggregates. To investigate whether MSCs aggregated into spherical clusters, i.e. spheroids, could alleviate experimental colitis, we created MSC spheroids in vitro and injected them in mice with established DSS-induced colitis. Since the inflammation is in the mucosa of the distal colon, we injected the MSC spheroids intraluminally via an enema, hypothesizing that MSC spheroids might integrate into the mucosa or release soluble factors which contribute to the attenuation of experimental colitis. We observed that intraluminal injection of in vitro generated MSC spheroids alleviated DSS-induced colitis when given in a high dose, which was accompanied by a decreased invasion of distinct immune cells and a reduced mucosal production of some proinflammatory cytokines.
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MATERIAL AND METHODS
MSC isolation
Murine bone marrow MSCs were isolated from 8 to 12-week-old C57BL/6Jico mice (Charles River Maastricht, The Netherlands). Mice were sacrificed by cervical dislocation and femurs and tibiae were removed, cleaned of tissue and flushed to retrieve bone marrow cells. Cells were plated in αMEM (Lonza, Verviers, Belgium) supplemented with 10% fetal calf serum (Hyclone, Thermo Scientific, Landsmeer, The Netherlands), 3mM L-glutamine (Invitrogen, Bleiswijk, The Netherlands) and Penicillin/Streptomycin (Lonza, Verviers, Belgium) after a centrifugation step and expanded in a 37°C humidified incubator containing 5% CO2. After 24 hours, non-adherent cells were removed and the medium was refreshed every 3-4 days. The protocol for the experiments was approved by the Committee on Animal Welfare of the Leiden University Medical Center.
MSC spheroid formation
Spheroids were formed in 96-wells culture plates (Greiner Bio-One BV, Alphen a/d Rijn, The Netherlands) of 2,500 MSCs per well. Thus, every spheroid consisted of 2,500 MSCs and 0.24% methyl cellulose (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands) which was added to the medium in each well to enhance spheroid formation. MSCs from passages 6 to 8 were used to create spheroids for transplantation experiments. Spheroids were harvested after 2 days of culture. Before in vivo injection, MSC spheroids were thoroughly washed with PBS. Either 0.5x10 6 or 2.0x10 6 MSCs in spheroids were injected locally meaning 200 spheroids consisting of 2,500 MSCs per spheroid in case of '0.5x10 6 MSCs in spheroids' and 800 spheroids consisting of 2,500 MSCs per spheroid in case of '2.0x10 6 MSCs in spheroids'.
In indicated in vitro experiments 500 U/ml recombinant mouse IL-6 (Life Technologies, Bleiswijk, The Netherlands) or recombinant mouse TNF-α (R&D systems, Abingdon, UK) was added to each well. In these experiments, in total 12-15 96-wells culture plates per time point were used to generate spheroids resulting in 1152-1440 spheroids per time point.
MSC characterization
Immunophenotyping of MSCs was performed using the following primary antibodies: CD44, CD105, CD106 (BD Biosciences, San Diego, CA, USA) CD29, Sca-1 and CD45 (eBioscience, Vienna, Austria). Samples were analyzed using a FACSCanto II flow cytometer with Diva Software (BD Biosciences, San Diego, CA, USA) and the data were analyzed with FlowJo software (version 8.7.1., Tree Star Inc. Ashland, OR, USA). In vitro differentiation was performed in 24-wells culture plates with MSCs at 80% confluency. MSC spheroids were transferred to 24-wells plates after 2 days of culture and 4 days before the start of differentiation. For osteogenic differentiation MSCs and spheroids were stimulated for 21 days in complete medium supplemented with 10 -8 M dexamethason, 50 μg/ml ascorbic acid and 10 mM β-glycerophosphate (all from Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Alkaline phosphatase activity was shown with Fast Blue and calcium deposit with Alizarin Red (both Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). For adipogenic differentiation, MSCs and spheroids were stimulated for 21 days in adipogenic differentiation medium consisting of complete medium supplemented with dexamethasone (10 -6 M), insulin (5 µM), indomethacin (100 μM) and 3-isobutyl-1-methylxanthine (0.5 mM) (all from Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands). Formation of lipid droplets was visualized with Oil-red O staining (Sigma-Aldrich Chemie BV, Zwijndrecht, The Netherlands).
Induction of colitis and intraluminal injection of MSCs
Animals were housed in individually ventilated cages and were given drinking water and food ad libitum. Colitis was induced in 8-week-old female C57BL/6Jico mice (Charles River Laboratories, The Netherlands) with 1.25% dextran sulphate sodium (DSS; MW 36,000-50,000 kDA; MP Biomedicals, Illkirch, France) supplied in the drinking water for 7 days. Five days after the introduction of DSS, mice received locally [with a 22 Gauge catheter (Abbocath, Hospira Benelux, Brussels, Belgium) approximately 3 cm from the anus] 0.5x10 6 or 2.0x10 6 MSCs in spheroids in 150 µl PBS (n = 7 and n = 14 respectively), or PBS alone (n = 7)
as a treatment control. The healthy control group consisted of 3 mice that received 2.0x10 6 MSCs in spheroids ('normal' group). In figure 1 the results of healthy control groups that received 0.5x10 6 MSCs in spheroids (n = 3), PBS (n = 3) or without treatment (n = 3) are shown. Mice were anesthetized with isoflurane and kept upside down for 5 minutes after injection. Mice were sacrificed 10 days after the start of the experiment. The separate endoscopy study consisted of 10 mice with DSS-induced colitis treated with 2.0x10 6 MSCs in spheroids and 9 mice treated with PBS. These mice were sacrificed 12 days after the start of the experiment to be able to evaluate mucosal healing.
Assessment of disease activity
Body weight was measured daily and disease progression and recovery were calculated as a percentage of weight loss from body weight at the start of the experiment. Furthermore, endoscopy was performed with the Coloview mini-endoscopic system of Karl Storz (Stöpler, Utrecht, The Netherlands) 18 larity of the mucosal surface and stool consistency. 18 MEICS was scored blindly and independently by two researchers. At sacrifice, blood was collected by cardiac puncture and centrifuged (10,000g for 10 minutes) to collect serum which was stored in -20°C. Colon length was measured, as an indicator of disease-related intestinal shortening, and colons were opened longitudinally to calculate the disease activity score consisting of the presence of loose stool, visible fecal blood and macroscopic inflammation using a scale of 0-3 per item, resulting in a maximum score of 9. 19 Colons were either stored in 4% neutral buffered A. 
Serum amyloid A and cytokine measurements
Serum amyloid A (SAA) levels were measured in the serum collected upon sacrifice using a solid phase sandwich ELISA kit (Life Technologies, Bleiswijk, The Netherlands).
Homogenates were prepared from distal colon with a Potter-Elvehjem glass homogenizer at 4°C in Greenberger lysis buffer (150 mM NaCl, 15 mM Tris, pH 7.4, 1 mM MgCl2, and 1%
Triton X-100). Samples were centrifuged for 15 minutes (11,000g at 4°C) and stored at -80°C.
The BCA Protein Assay Kit (Thermo Scientific Pierce, Etten-Leur, The Netherlands) was used to determine the total concentration of protein in the colons and cytokine levels of IFN-ɣ, IL-2, IL-4, IL-6, IL-10, IL-17a and TNF-α were measured using the Cytometric Bead Array System (BD Biosciences, San Diego, CA, USA) following the manufacturer's instructions.
Data was analysed with FlowJo software (version 8.7.1., Tree Star Inc. Ashland, OR, USA).
Cytokine levels measured were corrected for the amount of total protein.
MPO determination
Myeloperoxidase ( 
Statistical analysis
To compare two groups, parametric or nonparametric analyses were performed using an unpaired Student's t-test or Mann-Whitney U-test, respectively. Numerical values were expressed as means ± standard error of the mean (SEM). All analyses were performed using GraphPad Prism software (GraphPad Software, version 5.01, San Diego, CA). P values ≤0.05
were considered statistically significant. 
RESULTS
Intraluminally injected MSC spheroids alleviate DSS-induced colitis
The in vitro generated MSC spheroids had an average size of 148.9±3.8 µm (n = 6), a low expression of the apoptotic marker cleaved caspase-3 (figure 2A right panel) and every spheroid was constructed from 2,500 by flow cytometry characterized single cell MSCs ( figure 2B) . Similarly to single cell MSCs, MSC spheroids were able to differentiate into adipocytes and osteoblasts ( figure 2C ).
Subsequently, we examined whether our in vitro generated MSC spheroids could attenuate DSS-induced colitis. Mice received either 0.5x10 6 or 2.0x10 6 MSCs in spheroids intraluminally via an enema at day 5 when colitis was established. Treatment with 2.0x10 6 MSCs in spheroids resulted in significantly reduced body weight loss at sacrifice compared to treatment with 0.5x10 6 MSCs in spheroids or PBS (9.2% vs 16.4% and 15.9% respectively; both p = 0.02; figure 3A ). Moreover, disease related shortening of the colon was significantly reduced after treatment with 2.0x10 6 MSCs in spheroids compared to PBS (p < 0.05; figure   3B and 3C) which was also reflected in the macroscopic disease activity score consisting of the presence of loose stool, visible fecal blood and macroscopic inflammation at sacrifice (p = 0.01 compared to PBS; figure 3D ). In addition, histological evaluation of the distal colon 
Local treatment with MSC spheroids results in reduction of some inflammatory mediators
The systemic marker of inflammation SAA was drastically upregulated when DSS was induced indicating a severe colitis ( figure 6A ). Intraluminal treatment with 2.0x10 6 MSCs in spheroids resulted in a significant reduction of SAA in the serum at sacrifice compared to PBS treated mice (p = 0.04; figure 6A ). Locally, the number of neutrophils, as reflected by MPO activity, was significantly lower in the distal colons of mice treated with 2.0x10 6 MSCs in spheroids compared to PBS (p = 0.03; figure 6B ). In addition, lower numbers of macrophages were observed in the distal colon after MSC spheroids treatment (p = 0.06 for 0.5x10 6 MSCs in spheroids vs PBS and p = 0.08 for 2.0x10 6 MSCs in spheroids vs PBS; figure   6C and 6D).
Next, we measured the proinflammatory cytokines locally in the distal colon. In our hands, the Th1 and Th17-skewing cytokines TNF-α, IFN-ɣ, IL-6 and IL-17a were upregulated in the experimental colitis compared to normal controls. IFN-ɣ and to a lesser extent TNF-α were reduced in the distal colons in colitis after treatment with 2.0x10 6 MSCs in spheroids (IFN-ɣ, p < 0.05; figure 7A and 7B ). In addition, the level of local IL-6 was significantly reduced after treatment with MSC spheroids (p = 0.03 for both 0.5x10 6 and 2.0x10 6 MSCs in spheroids vs PBS; figure 7C ). IL-17a was, although not significant, also decreased after MSC spheroid treatment compared to PBS ( figure 7D ). IL-2 and IL-4 were not upregulated compared to healthy control, however treatment with 2.0x10 6 MSCs in spheroid significantly reduced both cytokines compared to PBS ( figure 7E and 7F ). Although MSC spheroid treatment reduced inflammatory responses and thereby alleviated colitis, levels of the regulatory cytokine IL-10 were not elevated compared to PBS or healthy controls ( figure 7G ). In addition, FoxP3 staining of the distal colons did not reveal major differences between Tregs in the MSC spheroid treated groups and the PBS treated mice ( figure 7H ).
TNF-α-stimulation of MSC spheroids enhances COX-2 dependent PGE2 secretion in vitro
COX-2 expression and subsequent production of PGE2 in inflamed colons has been identified as an important factor in the wound healing process in experimental colitis. 21, 22 To evaluate if MSC spheroids produce COX-2 dependent PGE2, we determined COX-2 RNA in MSC spheroids and PGE2 levels in the supernatant. In addition, MSC spheroids were stimulated with IL-6 or TNF-α at the start of culture (day -1 in figure 8) since these cytokines were significantly elevated in DSS-induced colitis. Adding IL-6 to MSCs at the start of spheroid induction did not affect the expression of COX-2 RNA ( figure 8A ). In concordance with this result, PGE2 levels in the supernatants were comparable to those in non-stimulated MSC spheroids ( figure 8B) . When TNF-α was added at the start of spheroid induction, already 1 day later COX-2 RNA expression was increased compared to non-or IL-6 stimulated MSC spheroids ( figure 8A) . Moreover, PGE2 levels in the supernatants of TNF-α-stimulated MSC spheroid culture were elevated compared to non-or IL-6 stimulated MSC spheroids ( figure   8B ). without stimulation, with IL-6-stimulation (500 U/ml) or TNF-α-stimulation (500 U/ml) at day -1. Every day MSC spheroids were harvested to evaluate COX-2 RNA expression in the MSC spheroids (day 0: *, p = 0.02 no stimulation vs TNF-α; *, p = 0.01 IL-6 vs TNF-α; day 1: **, p = 0.002 both no stimulation and IL-6 vs TNF-α; day 2: **, p = 0.003 no stimulation vs TNF-α; **, p = 0.002 IL-6 vs TNF-α; day 3: **, p = 0.007 no stimulation vs TNF-α; **, p = 0.003 IL-6 vs TNF-α; day 4: *, p = 0.02 no stimulation vs TNF-α; *, p = 0.01 IL-6 vs TNF-α). (B): PGE2-levels in culture medium of MSC spheroids stimulated with IL-6, TNF-α or without stimulation (day 0: ns; day 1: ***, p = 0.0001 both no stimulation and IL-6 vs TNF-α; day 2: *, p = 0.05 no stimulation vs TNF-α; *, p = 0.03 IL-6 vs TNF-α; day 3: **, p = 0.002 no stimulation vs TNF-α; *, p = 0.03 IL-6 vs TNF-α; day 4: ns no stimulation vs TNF-α; *, p = 0.05 IL-6 vs TNF-α).
DISCUSSION
Recently, MSCs were observed to form aggregates in the peritoneum which produced TSG-6 and thereby attenuated DSS-induced colitis. 16 In addition, in an experimental myocardial infarction model intravenously injected MSCs entrapped within the lungs where they also formed aggregates that produced TSG-6 resulting in less myocardial damage. 17 Not only in experimental disease models, but also in healthy state, MSCs tend to spontaneously form spheroids. 16, 23 Therefore, we hypothesized that the formation of spheroids is important for MSCs to gain their immunosuppressive effects. In this present study, we observed that intraluminal treatment with in vitro generated MSC spheroids alleviated moderately-severe DSS-induced colitis, however, only when a high dose of 2.0x10 6 MSCs in spheroids was given.
Body weight loss and disease activity score at sacrifice were significantly reduced after and/or endoscopic remission. 24, 25 In addition, a retrospective study showed that in patients with clinical remission, the presence of mucosal inflammation was not associated with more complications or exacerbations during a median follow-up of 6.8 years. 26 Biochemically, the systemic marker of inflammation SAA was elevated after DSS-induced mucosal damage possibly as a result of bacterial invasion. Similarly to other acute phase proteins, SAA is mainly produced in the liver. In addition, SAA is also secreted into the lumen by colonic epithelial cells especially in case of inflammation and tissue destruction. 27, 28 Locally, SAA can promote IL-6 and TNF-α production by macrophages. 29, 30 Indeed, both IL-6
and TNF-α were drastically upregulated after DSS administration. Although not significantly, histological evaluation demonstrated that the number of macrophages in the mucosa of the distal colon was decreased after local MSC spheroid treatment compared to PBS. Moreover, SAA-, IL-6-and TNF-α-levels were reduced. We cannot ensure that IL-6-and TNF-α were only produced by macrophages as dendritic cells and T cells are also able to produce these cytokines, however, macrophages are identified to be of crucial importance in the innate intestinal immunity. Mice deficient for macrophages or depleted for local gut macrophages are less susceptibility to experimental colitis than wild type mice. 31, 32 Moreover, DSS administration to lymphocyte-deficient mice leads to the development of colitis, indicating that macrophages are the key players in establishing DSS-induced colitis and that lymphocytes are of less importance herein. 33 In our experiments, IL-17a was elevated in DSSinduced colitis and dose-dependently reduced after intraluminal treatment with MSC spheroids. Since secreted IL-17a is reported to regulate migration of neutrophils to the place of inflammation 34, 35 , we examined the amount of neutrophils in the distal colons. The amount of neutrophils was significantly lower after intraluminal treatment with 2.0x10 6
MSCs in spheroids.
The exact mechanism of MSC spheroid-mediated attenuation of DSS-induced colitis remains partially unclear as no MSC spheroids were found in the colon of treated mice at sacrifice.
Both MSCs as well as the supernatants from MSCs are reported to be able to reduce the levels of IL-6 and TNF-α secreted by activated macrophages and to increase the production of IL-10 resulting in the polarisation towards regulatory M2 macrophages. [36] [37] [38] We observed that IL-6 and TNF-α levels, and the number of macrophages in the mucosa of the distal colons were reduced, suggesting that in this model at time of sacrifice no regulatory macrophages were induced but rather that the number of macrophages was decreased as a sign of reduced inflammation after MSC spheroid treatment. In line with these results, an increased recruitment of macrophages to the place of acute myocardial infarction was found to facilitate cardiac muscle repair by MSCs as no attenuation of disease was observed when macrophage recruitment was diminished or MSCs were removed after local macrophage infiltration. 39 This indicates that the interaction between MSCs and macrophages might be an important factor in restoring cardiac function suggesting that the number of local macrophages will be decreased as a sign of attenuated disease when cardiac function is restored.
In our hands, IL-10 levels in homogenates of the distal colons at sacrifice were similar between MSC spheroids treated mice and mice that received PBS and not significantly elevated compared to healthy controls. Although IL-10 has been described to be of major importance in the homeostasis of the colonic milieu 40, 41 , clinical trials using IL-10 as a treatment for Crohn's disease have failed to show superiority of IL-10 therapy. 42 In addition, MSCs cocultured in vitro with activated NK cells resulted in reduced levels of IL-10. 43 On the other hand, when MSCs were cocultured in vitro with dendritic cells, IL-10 production was elevated. 44 MSCs are reported to be able to inhibit Th17 cell differentiation and subsequent IL-17a production which was restored when COX-2 was inhibited or PGE2 secretion by MSCs was blocked, suggesting that COX-2 dependent PGE2 is at least one of the paracrine factors MSCs produce to gain their immunosuppressive effects. [45] [46] [47] Whether or not direct cell-to-cell contact between MSCs and CD4-positive T cells is needed for the suppression of Th17 cell differentiation is doubtful as previous published papers are not consistent. In our present study, however, we do not assume that direct contact between IL-17a-producing cells and intraluminally injected MSC spheroids is the explanation of the alleviated colitis since even with scrutinous histological evaluation, we have never observed the intraluminally injected MSC-spheroids in the damaged or healed mucosa. In addition, we generated MSC spheroids with GFP-positive MSCs and injected them intraluminally in mice with DSS-induced colitis and these MSCs were not found in the mucosa (figure 9). Thus, engraftment of the MSC spheroids in the mucosa does not seem to have occurred.
Interestingly, supernatants from co-cultures between Th17 cells and MSCs have been
reported to contain elevated PGE2 levels compared to culture of only CD4-positive T cells or MSCs suggesting that this soluble factor is at least one of the key player in the suppressed differentiation. 47 In addition, spheroid formation was reported to induce increased expression of COX-2-dependent PGE2 both in vitro as in vivo. 23 In line with those results, we observed that MSC spheroids constantly produced considerable but relatively low levels of COX-2 and PGE2 in vitro which increased over time especially when stimulated with TNF-α.
However, in our in vitro model, we started with the priming of MSCs before they aggregated into spheroids, whereas in vivo, if at all, stimulation took place after the formation of spheroids. Interestingly, TNF-α induces the expression of COX-2 in colonic epithelial cells of patients with IBD and mice with DSS colitis thereby promoting epithelial wound healing. [48] [49] [50] [51] Wound healing was even impaired in COX-2 -/mice with DSS-induced colitis as a result of an inability to increase colonic PGE2. 22 Moreover, intraperitoneal administration of PGE2 restored DSS-induced decrease of proliferating epithelial cells indicating a key role for PGE2 in mucosal repair. 52 We hypothesize that the observed elevated levels of TNF-α in the A.
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inflamed colons possibly resulted in priming of intraluminally injected MSC spheroids to produce high amounts of PGE2 subsequently promoting colonic epithelial wound healing without engraftment of the spheroids within the damaged mucosa. Supporting our hypothesis, rectal administration of basic fibroblast growth factor ameliorated DSS-induced colitis by activating COX-2 RNA which resulted in accelerated mucosal healing rather than a direct immunosuppressive effect on T cells. 21 However, all these hypotheses are made with utmost caution since we did not offer direct evidence that supports an interaction between the intraluminal injected spheroids and TNF-α and/or the colonic mucosa. In addition, we did not evaluate other possible mediators such as TSG-6 and transforming growth factor-beta.
Taken together, our results demonstrate that intraluminal injection of in vitro generated MSC spheroids at least partially attenuate DSS-induced colitis. The dose is important since only 2.0x10 6 MSCs in spheroids resulted in significantly less body weight loss and lower disease activity score accompanied by a reduction of systemic inflammation, some colonic cytokines, and neutrophils in the distal colon.
